Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
46 hedge funds and large institutions have $79.4M invested in Genocea Biosciences, Inc. in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 8 closing their positions.
322% more call options, than puts
Call options by funds: $843K | Put options by funds: $200K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
10% more funds holding
Funds holding: 42 → 46 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less capital invested
Capital invested by funds: $86.3M → $79.4M (-$6.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.03M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$292K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$169K |
| 4 |
CC
Commodore Capital
New York
|
+$139K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$565K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$514K |
| 3 |
Two Sigma Advisers
New York
|
-$376K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$347K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$219K |
GNCA Hedge Fund Activity: Q2 2021 in Review
46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2021, worth a combined $79.4M — down 8% from $86.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GNCA positions and 8 closed out — a net gain of 4 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $6.03M. The largest seller was Two Sigma Investments, cutting an estimated $565K.
- 46 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2021, up from 42 in Q1 2021.
- Funds reported $79.4M of Genocea Biosciences, Inc. stock for Q2 2021, down 8% quarter-over-quarter.
- 12 funds opened new Genocea Biosciences, Inc. positions in Q2 2021 and 8 closed out, a net change of +4 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2021 was Point72 Asset Management, an estimated $6.03M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2021 was Two Sigma Investments, an estimated $565K sold.
Based on aggregated 13F filings for Q2 2021.